La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Mochida Pharmaceutical Résultats passés
Passé contrôle des critères 1/6
Mochida Pharmaceutical's earnings have been declining at an average annual rate of -0.7%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 0.06% per year. Mochida Pharmaceutical's return on equity is 3.5%, and it has net margins of 4.3%.
Informations clés
-0.7%
Taux de croissance des bénéfices
0.8%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 3.4% |
| Taux de croissance des recettes | -0.06% |
| Rendement des fonds propres | 3.5% |
| Marge nette | 4.3% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Aug 08
Mochida Pharmaceutical (TSE:4534) Is Paying Out A Dividend Of ¥40.00
Jul 25Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Jul 11Mochida Pharmaceutical's (TSE:4534) Dividend Will Be ¥40.00
Mar 22Mochida Pharmaceutical (TSE:4534) Will Pay A Dividend Of ¥40.00
Mar 02Ventilation des recettes et des dépenses
Comment Mochida Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 103,545 | 4,413 | 33,790 | 12,554 |
| 31 Mar 24 | 102,885 | 4,547 | 33,713 | 12,554 |
| 31 Dec 23 | 100,085 | 3,012 | 34,059 | 13,283 |
| 30 Sep 23 | 99,537 | 5,564 | 31,738 | 13,283 |
| 30 Jun 23 | 100,316 | 5,182 | 33,021 | 13,283 |
| 31 Mar 23 | 103,261 | 6,649 | 33,324 | 13,283 |
| 31 Dec 22 | 106,759 | 8,470 | 32,899 | 12,295 |
| 30 Sep 22 | 109,370 | 9,576 | 33,218 | 12,295 |
| 30 Jun 22 | 110,509 | 11,071 | 32,086 | 12,295 |
| 31 Mar 22 | 110,179 | 10,569 | 32,866 | 12,295 |
| 31 Dec 21 | 107,928 | 10,360 | 33,967 | 10,849 |
| 30 Sep 21 | 105,381 | 8,092 | 34,834 | 10,849 |
| 30 Jun 21 | 102,978 | 7,873 | 33,907 | 10,849 |
| 31 Mar 21 | 102,995 | 8,587 | 31,939 | 10,849 |
| 31 Dec 20 | 102,583 | 6,627 | 30,517 | 11,884 |
| 30 Sep 20 | 101,910 | 5,417 | 30,740 | 11,884 |
| 30 Jun 20 | 102,690 | 4,660 | 31,418 | 11,884 |
| 31 Mar 20 | 101,799 | 4,598 | 31,228 | 11,884 |
| 31 Dec 19 | 101,102 | 4,964 | 31,366 | 13,003 |
| 30 Sep 19 | 103,919 | 6,091 | 30,284 | 13,003 |
| 30 Jun 19 | 106,331 | 5,897 | 30,665 | 13,003 |
| 31 Mar 19 | 109,643 | 8,435 | 30,581 | 13,003 |
| 31 Dec 18 | 110,669 | 9,602 | 30,602 | 11,912 |
| 30 Sep 18 | 109,409 | 10,037 | 30,770 | 11,912 |
| 30 Jun 18 | 107,550 | 10,548 | 29,849 | 11,912 |
| 31 Mar 18 | 106,761 | 9,023 | 29,992 | 11,912 |
| 31 Dec 17 | 108,042 | 8,001 | 29,266 | 15,226 |
| 30 Sep 17 | 105,511 | 8,886 | 28,707 | 15,226 |
| 30 Jun 17 | 101,852 | 9,569 | 28,489 | 15,226 |
| 31 Mar 17 | 97,349 | 8,526 | 29,710 | 15,226 |
| 31 Dec 16 | 93,140 | 9,547 | 29,764 | 13,454 |
| 30 Sep 16 | 93,337 | 8,897 | 30,183 | 13,454 |
| 30 Jun 16 | 94,138 | 8,226 | 30,817 | 13,454 |
| 31 Mar 16 | 92,272 | 8,150 | 29,391 | 13,454 |
| 31 Dec 15 | 92,138 | 9,449 | 28,921 | 11,777 |
| 30 Sep 15 | 90,200 | 9,262 | 28,018 | 11,777 |
| 30 Jun 15 | 89,467 | 8,823 | 29,131 | 11,777 |
| 31 Mar 15 | 87,252 | 7,544 | 29,881 | 11,777 |
| 31 Dec 14 | 89,529 | 7,881 | 31,561 | 11,961 |
| 30 Sep 14 | 91,037 | 8,585 | 32,209 | 11,961 |
| 30 Jun 14 | 92,015 | 9,872 | 31,139 | 11,961 |
| 31 Mar 14 | 93,947 | 9,892 | 31,026 | 11,961 |
| 31 Dec 13 | 92,291 | 10,171 | 29,503 | 12,519 |
| 30 Sep 13 | 90,902 | 8,404 | 30,934 | 12,519 |
Des revenus de qualité: 4534 a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: 4534's current net profit margins (4.3%) are lower than last year (5.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 4534's earnings have declined by 0.7% per year over the past 5 years.
Accélération de la croissance: 4534's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 4534 had negative earnings growth (-14.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.6%).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de 4534 ( 3.5% ) est considéré comme faible.